TARS
Tarsus Pharmaceuticals, Inc. Common Stock#48 · 2024EPAYearly return
+175%
Peak return
+183%
Max drawdown
-53%
ADR (20 days)
+4.9%
Base
24 days / -26.2%
Prior run
+167%
Breakout volume
3.1x
Pivot
$33.53
Catalyst Earnings/Guidance2024-02-27Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business AchievementsGlobeNewswire Inc.
Earnings, Guidance oder Umsatz-/EPS-Revision als Neubewertungsanker.
Healthcare · Healthcare & Biotech
Continue in the full Atlas
Drawing, alerts, replay and the live scanner built on the same criteria are part of WickedDesk. Compare TARS with the current market directly.